Clinical trials authorised for 3D-printed ulcerative colitis drug
European Pharmaceutical Review
NOVEMBER 22, 2022
Radio-imaging agents embedded in specific components of the dosage form were added in early development of the formulation to assess and confirm the location of drug release in the GI tract. The first 3D-printed pharmaceutical , SpritamĀ® (a levetiracetam tablet) was approved by the FDA in July 2015.
Let's personalize your content